OmicsDI
Toggle navigation
Browse
Submit Data
Databases
API
Help
Advanced
Search
27
Results
Show all
Save search
Copy query
Show results for
Unknown
(27)
Publication Date
Release Date
2021
(10)
2023
(5)
2022
(5)
2025
(3)
2020
(2)
2024
(1)
2017
(1)
Previous
page
1 / 3
You're on page
1
page
2
page
3
Next
page
Sort
by:
Relevance
Page size
10
Therapeutic Anticoagulation with Heparin in Critically Ill Patients with Covid-19.
Not available
S-EPMC8362592
|
biostudies-literature
Cite
Therapeutic Anticoagulation with Heparin in Noncritically Ill Patients with Covid-19.
Not available
S-EPMC8362594
|
biostudies-literature
Cite
Rare predicted loss-of-function variants of type I IFN immunity genes are associated with life-threatening COVID-19.
Not available
S-EPMC10074346
|
biostudies-literature
Cite
X-linked recessive TLR7 deficiency in ~1% of men under 60 years old with life-threatening COVID-19.
Not available
S-EPMC8532080
|
biostudies-literature
Cite
Inborn errors of type I IFN immunity in patients with life-threatening COVID-19.
Not available
S-EPMC7857407
|
biostudies-literature
Cite
Effect of Hydrocortisone on Mortality and Organ Support in Patients With Severe COVID-19: The REMAP-CAP COVID-19 Corticosteroid Domain Randomized Clinical Trial.
Not available
S-EPMC7489418
|
biostudies-literature
Cite
Interleukin-6 Receptor Antagonists in Critically Ill Patients with Covid-19.
Not available
S-EPMC7953461
|
biostudies-literature
Cite
Pharmacomechanical Catheter-Directed Thrombolysis for Deep-Vein Thrombosis.
Not available
S-EPMC5763501
|
biostudies-literature
Cite
Mapping the human genetic architecture of COVID-19.
Not available
S-EPMC8674144
|
biostudies-literature
Cite
Effect of Convalescent Plasma on Organ Support-Free Days in Critically Ill Patients With COVID-19: A Randomized Clinical Trial.
Not available
S-EPMC8491132
|
biostudies-literature
Cite
Previous
page
1 / 3
You're on page
1
page
2
page
3
Next
page
Sort
by:
Relevance
Page size
10
OmicsDI
is part of the ELIXIR infrastructure
OmicsDI is an Elixir interoperability service.
Learn more ›
Tweets